Amgen loses high court decision over cholesterol drug

PIONEER—Amgen is a worldwide leader in biotechnology, established in Thousand Oaks in 1980. Acorn file photoIn a long-running patent dispute that went all the way to the U.S. Supreme Court, local drugmaker Amgen lost a decision to French rival Sanofi over who has the rights to cholesterol-fighting drugs.
The May 18 ruling was a resounding defeat for Amgen, with all nine justices ruling against the Thousand Oaks-headquartered company.
The legal battle concerned medications that lower so-called ba...

Oops! An active online subscription is required to access this content.

Please login below or Subscribe today!